T1	Participants 150 386	240 patients with acute myocardial infarction were analyzed from a randomized trial of intravenous anistreplase (Eminase), also known as anisoylated plasminogen streptokinase activator complex (APSAC), versus intracoronary streptokinase
T2	Participants 772 802	35% of all reperfused patients
T3	Participants 637 661	total patient population
T4	Participants 804 826	Half of these patients
T5	Participants 1101 1183	frequent alterations in coronary blood flow occur early during reperfusion therapy
